Rob Dillard

DocwireNews

A large-scale UK trial of <a href="https://www.docwirenews.com/abstracts/journal-abstracts/the-mitochondrial-landscape-of-ovarian-cancer-emerging-insights/">ovarian cancer</a> screening was unable to reduce deaths from the disease, according to a study published in The Lancet.
In this study, researchers examined more than 200,000 women aged 50-74 who were randomly assigned to one of three groups: no screening, annual screening using an ultrasound scan, and annual multimodal screening involving a blood test followed by an ultrasound scan as a second line test. The population of interest were followed for an average of 16 years.
The results showed that while  multimodal testing succeeded at detecting early-stage cancer, neither screening method led to a reduction in deaths. According to researchers, the results highlight the importance of requiring evidence that screening actually reduces deaths instead of just offering early detection.
Professor Ian Jacobs, from the University of New South Wales (UNSW Sydney), a co-investigator who has led the ovarian cancer screening research program since 1985 and who was lead investigator of UKCTOCS from 2001-2014, said via a <a href="https://www.eurekalert.org/pub_releases/2021-05/ucl-sfo051321.php">press release</a>: &#8220;My thanks to the thousands of women, healthcare professionals and researchers who made this trial possible. The multimodal screening strategy did succeed in detection of ovarian cancer at an earlier stage, but sadly that did not save lives. This is deeply disappointing and frustrating given the hope of all involved that we would save the lives of thousands of women who are affected by ovarian cancer each year.&#8221;
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Results from <a href="https://twitter.com/hashtag/UKCTOCS?src=hash&amp;ref_src=twsrc%5Etfw">#UKCTOCS</a>: Given that screening did not significantly reduce ovarian and tubal cancer deaths, general population screening for <a href="https://twitter.com/hashtag/OvarianCancer?src=hash&amp;ref_src=twsrc%5Etfw">#OvarianCancer</a> cannot be recommended. Published <a href="https://twitter.com/hashtag/OpenAccess?src=hash&amp;ref_src=twsrc%5Etfw">#OpenAccess</a> in <a href="https://twitter.com/TheLancet?ref_src=twsrc%5Etfw">@TheLancet</a> <a href="https://t.co/VK49QvWMvb">https://t.co/VK49QvWMvb</a> <a href="https://t.co/IE3jtIxUVX">pic.twitter.com/IE3jtIxUVX</a>
&mdash; MRC Clinical Trials Unit at UCL (@MRCCTU) <a href="https://twitter.com/MRCCTU/status/1392759982559481858?ref_src=twsrc%5Etfw">May 13, 2021</a>
</blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
&nbsp;
Professor Jacobs noted: &#8220;Population screening for ovarian cancer can only be supported if a test is shown to reduce deaths in a future randomised controlled trial. I remain hopeful that a new effective screening test will be found eventually, but it will take many years to conduct a large trial of the test. Realistically, this means we have to reluctantly accept that population screening for ovarian cancer is more than a decade away.&#8221;
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Research has found that screening women for <a href="https://twitter.com/hashtag/OvarianCancer?src=hash&amp;ref_src=twsrc%5Etfw">#OvarianCancer</a> did not reduce deaths, despite one of the screening methods tested detecting cancers earlier. Find out more: <a href="https://t.co/NLgJFO0asY">https://t.co/NLgJFO0asY</a><a href="https://twitter.com/hashtag/NIHRfunded?src=hash&amp;ref_src=twsrc%5Etfw">#NIHRfunded</a> <a href="https://twitter.com/hashtag/UKCTOCS?src=hash&amp;ref_src=twsrc%5Etfw">#UKCTOCS</a><a href="https://twitter.com/TheLancet?ref_src=twsrc%5Etfw">@TheLancet</a> <a href="https://t.co/ykcRxUD6YJ">pic.twitter.com/ykcRxUD6YJ</a>
&mdash; NIHR Research (@NIHRresearch) <a href="https://twitter.com/NIHRresearch/status/1392814387577098243?ref_src=twsrc%5Etfw">May 13, 2021</a>
</blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Screening the population regularly for ovarian cancer did not reduce deaths from the disease, a UK study has found <a href="https://t.co/MB1FphjnaI">https://t.co/MB1FphjnaI</a>
&mdash; Sky News (@SkyNews) <a href="https://twitter.com/SkyNews/status/1392823801327636484?ref_src=twsrc%5Etfw">May 13, 2021</a>
</blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
&nbsp;
&nbsp;
&nbsp;

Laura Litwin

Are There Gender Disparities in Lung Cancer Screening Outcomes Among People Who Have Never Smoked?

Lung Cancer

Thomas Ruggia

Study Shows Positive Data for Implantable Telescope for Late-Stage Age-Related Macular Degeneration

Ophthalmology

Amber Sanchez, MD

Charlotte Robinson

Apheresis in Nephrology Practice

Nephrology Times

Latest News

Large-Scale Trial of Ovarian Cancer Screening Fails to Reduce Deaths

Ovarian Cancer

A large-scale UK trial of ovarian cancer screening was unable to reduce deaths from the disease, according to a study published in The Lancet. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe